Wednesday, November 20, 2024
The phase 1/2 trial will compare the IOP-reducing effect of SpyGlass Pharma's bimatoprost-eluting IOL to treatment with timolol ophthalmic solution in glaucoma patients undergoing cataract surgery.
Friday, November 15, 2024
Results of MediPrint Ophthalmics’s phase 2b trial for LL-BMT1, presented at AAOpt, indicated that the lenses could be a safe and effective alternative to daily glaucoma drops.
Tuesday, November 12, 2024
Now available in the United States, the objectiveFIELD bilateral visual field analyzer measures pupillary responses to spatially resolved stimuli.
Monday, October 28, 2024
The new director of the FDA’s Center for Devices and Radiological Health brings 15 years of FDA experience and a background in ophthalmology.
Friday, October 25, 2024
The company presented 18-month data at Eyecelerator that showed sustained IOP reduction after cataract surgery.
Wednesday, October 23, 2024
Researchers found the Optejet technology reduces the harmful effect of preservatives in multiuse latanoprost eye drops.
Wednesday, October 23, 2024
Research presented at AAO shows clinics discard most eye drops long before expiration.
Friday, October 11, 2024
The new slit lamp tonometer offers a combination of iCare rebound technology and slit-lamp based tonometry
Thursday, September 26, 2024
The company says the Micor 700’s non-ultrasound approach minimizes thermal stress and tissue damage during cataract surgery.
Wednesday, September 25, 2024
The Omnicad platform combines high-definition imaging and artificial intelligence for easier diagnosis of ocular surface disease.
Tuesday, September 24, 2024
Research also highlights a potential link between allostatic load, which is a stress measurement, and racial disparities in glaucoma prevalence.
Monday, September 23, 2024
The deal includes Vista 1-Step and Vista IS products, which are intended to enhance vitrectomy procedures.
Monday, September 23, 2024
The agreement aims to explore the therapeutic potential of Nicox’s nitric oxide-donating PDE5 inhibitor, NCX 1728, in glaucoma treatment.
Monday, September 23, 2024
The collaboration focuses on developing RTC-620, a biodegradable implant that is designed to reduce intraocular pressure.
Thursday, September 12, 2024
Study demonstrates the effectiveness of Iantrek’s biointerventional technology in treating open-angle glaucoma.
Sunday, September 8, 2024
Cup-type hemorrhages linked to faster disease progression.
Sunday, September 8, 2024
A long-term study supports the impact of IOP reduction on the progression of glaucoma in highly myopic patients.
Sunday, September 8, 2024
Agency considers merging jurisdictions and extending contracts to improve efficiency.
Sunday, September 8, 2024
New study shows sustained IOP reduction and decreased medication dependence in patients implanted with a cilioscleral interpositioning device.
Thursday, August 29, 2024
The IOP-Connect device, currently under development, will provide real-time IOP monitoring from inside the eye.
Tuesday, August 20, 2024
Novel surgical approach demonstrates significant IOP and medication reductions.
Tuesday, August 20, 2024
Company officials say the merger will strengthens their ophthalmic portfolio and accelerate commercialization of products.
Tuesday, August 20, 2024
Preserflo device shows efficacy and safety comparable to traditional filtering surgery in a 2-year study.
Tuesday, August 20, 2024
Ahmed ClearPath glaucoma drainage device demonstrates safety and effectiveness over 3 years.
Tuesday, August 20, 2024
A study using rabbit models finds the Wistend microstent safe and effective in reducing IOP.
Monday, August 12, 2024
Online circular contrast perimetry demonstrates good repeatability and reliability in glaucoma screening and monitoring, study finds.
Tuesday, August 6, 2024
A Rutgers study analyzes 20 years of FDA records, finding some lesser-known drugs linked to reports of POAG.
